Live

G

$GPCR

2 articles found

1 positive

0 negative

1 neutral

Structure Therapeutics' Aleniglipron Posts Blockbuster Phase 2 Data, Rivaling Injectable GLP-1s

GlobeNewswire Inc.

GlobeNewswire Inc.·Mar 16·Structure Therapeutics Inc.

Structure Therapeutics' Aleniglipron Posts Blockbuster Phase 2 Data, Rivaling Injectable GLP-1s

Structure Therapeutics reports Phase 2 data for oral GLP-1 agonist aleniglipron showing 16.3% weight loss, matching injectable competitors with better tolerability.

GPCRPhase 2 clinical trialFDA approval

Patent Strength, Not Clinical Data, to Drive GLP-1 Market Leadership

GlobeNewswire Inc.

GlobeNewswire Inc.·Feb 26·Patentvest

Patent Strength, Not Clinical Data, to Drive GLP-1 Market Leadership

Patent strength, not clinical efficacy, will drive GLP-1 market leadership as clinical outcomes converge. Companies with robust IP portfolios may capture disproportionate market share despite comparable results.

PFELLYNVORHHBYAZN+2GLP-1 drugsoral small-molecule

$GPCR Stock News & Sentiment | MarketPulse